Organovo (ONVO)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	3.32 mm	3.32 mm	3.32 mm	3.32 mm	3.32 mm	3.32 mm
Cash burn (monthly)	(no burn)	631.67 k	869.33 k	1.12 mm	849.67 k	990.92 k
Cash used (since last report)	n/a	1.76 mm	2.43 mm	3.14 mm	2.37 mm	2.77 mm
Cash remaining	n/a	1.55 mm	889.31 k	175.56 k	944.23 k	549.77 k
Runway (months of cash)	n/a	2.5	1.0	0.2	1.1	0.6

Beta Read what these cash burn values mean

Financial data from Organovo earnings reports.

Institutional ownership, Q2 2024

ONVO institutional ownership history Ownership history

13.0% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	16	31	-48.4%
Opened positions	5	23	-78.3%
Closed positions	20	1	+1900.0%
Increased positions	3	0	NEW
Reduced positions	2	1	+100.0%

13F shares	Current	Prev Q	Change
Total value	861.50 mm	762.54 mm	+13.0%
Total shares	1.13 mm	838.13 k	+34.9%
Total puts	0.00	0.00
Total calls	18.80 k	0.00	NEW
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Armistice Capital	929.00 k	$707.99 mm	NEW
Citadel Advisors	79.26 k	$60.40 mm	NEW
MS Morgan Stanley	41.92 k	$31.95 mm	-0.5%
Two Sigma Securities	29.78 k	$22.70 mm	+153.6%
STT State Street	27.83 k	$21.21 mm	0.0%
Raymond James & Associates	19.62 k	$14.95 mm	-1.0%
Albion Financial	1.91 k	$1.46 mm	0.0%
Quintet Private Bank	436.00	$381.00 k	+1.2%
BAC Bank of America	371.00	$283.00 k	NEW
Simplex Trading	134.00	$0.00	+59.5%

Largest transactions	Shares	Bought/sold	Change
Armistice Capital	929.00 k	+929.00 k	NEW
Vanguard	0.00	-353.61 k	EXIT
BLK BlackRock	0.00	-142.21 k	EXIT
Renaissance Technologies	0.00	-97.79 k	EXIT
Citadel Advisors	79.26 k	+79.26 k	NEW
Geode Capital Management	0.00	-74.91 k	EXIT
XTX Topco	0.00	-22.63 k	EXIT
Two Sigma Securities	29.78 k	+18.04 k	+153.6%
UBS UBS	0.00	-15.11 k	EXIT
NTRS Northern Trust	0.00	-14.67 k	EXIT

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

ONVO insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	#Shares	#Remaining
17 Nov 23	Murphy Keith	Common Stock	Grant	Acquire A	No	No	19,607	113,034
17 Nov 23	Vaidehi Joshi	Common Stock	Grant	Acquire A	No	No	19,607	39,214
17 Nov 23	Stern Adam K	Common Stock	Grant	Acquire A	No	No	19,607	39,214
17 Nov 23	Douglas Jay Cohen	Common Stock	Grant	Acquire A	No	No	19,607	49,214
17 Nov 23	Alison Tjosvold Milhous	Common Stock	Grant	Acquire A	No	No	19,607	39,214

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

Organovo To Present Clinical Data Of FXR314 In Phase 2 MASH In An Oral Presentation At The Liver Meeting Sponsored By The American Association For The Study Of Liver Diseases

13 Nov 24

Organovo Holdings, Inc. (NASDAQ:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) including ulcerative colitis, today announces that its

Press releases

From Benzinga Pro

Organovo Presents Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting

20 Nov 24

SAN DIEGO, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) including

Organovo to Present Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting Sponsored by the American Association for the Study of Liver Diseases

13 Nov 24

SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) including